Breaking Hormone Barriers in Breast Cancer Treatment

Combining a new oral drug with conventional treatments proves promising in boosting treatment effectiveness by overcoming hormone resistance in breast cancer as per a collaborative study between LSU Health New Orleans School of Medicine, the University of Rochester, and Cellestia Biotech AG, a biopharmaceutical company headquartered in Basel, Switzerland, published online in MDPI Cancers ().

CB-103 is a small molecule Notch inhibitor invented by Cellestia. Notch receptors relay information from the cell surface to the genes, and Notch signaling plays an important role in many different cancers, including breast cancers, where its role was originally demonstrated by the Miele laboratory.

Breast Cancer Management: Advances
The crab that invades the breast is no more a fear factor with all the advancements that medical science and customized protocols can fight breast cancer. the recent developments in the management of breast cancer.

‘Breakthrough study demonstrates the synergy of an investigational oral medication with standard therapies, reversing hormone resistance in Estrogen-Receptor Positive (ER+) and Triple-Negative Breast Cancers (TNBC) experimental models. # Breast Cancer, #Hormone Resistance, #Triple-Negative Breast Cancers ’

Tweet it Now

Based on their prior research, the LSU Health team believed this compound should be safe and effective in hormone-resistant estrogen-receptor-positive breast cancers and proposed the study for this indication to Cellestia.

“Over the past two decades, various drugs targeting the Notch signaling axis have been investigated,” notes senior author Lucio Miele, MD, Ph.D., Professor and Chair of Genetics and Assistant Dean for Translational Science at LSU Health New Orleans School of Medicine.

“CB-103 is a next-generation, orally active, clinical-stage drug that, unlike older drugs, directly targets gene regulation by Notch and offers a much-improved toxicity profile.”

Oral Drug Combo Targets Hormone Resistance in Breast Cancer

"The safety and efficacy of CB-103 in Notch-dependent advanced, metastatic solid, or hematological malignancies have been investigated in a multi-center international phase I/II clinical trial,” adds Samarpan Majumder, Ph.D., Assistant Professor of Genetics at LSU Health New Orleans School of Medicine and one of the senior authors of the paper.

Screening for Breast Cancer with Clinical Breast Examination
Clinical breast examination is a simple and inexpensive method of detecting breast cancer especially in women who do not have access to mammography.

“CB-103 has been safe and well-tolerated, showing minimal gastrointestinal toxicity, unlike previous Notch inhibitors."

Despite recent advances in the treatment of estrogen-receptor-positive breast cancers, endocrine resistance ultimately develops.

Triple-Negative Breast Cancer
Triple-negative breast cancers are ER negative, PR negative, and lack overexpression of HER-2. They are difficult to treat and are very aggressive.

Available second-line therapies are moderately effective but can have significant toxicities, and third-line therapies are generally largely ineffective. Triple-negative breast cancer is an aggressive breast cancer subtype that accounts for 15−25% of all breast cancer diagnoses in Western countries.

Patients with early TNBC have a two- to three-fold higher risk of disease recurrence and death in the first three years after diagnosis. TNBC disproportionately affects young premenopausal women and African American women.

“Our translational data will be serving as a foundation for planned clinical trials where we will combine CB-103 with anti-estrogen therapy in ER+ breast cancers and with taxanes like taxol or docetaxel in TNBC,” concludes Dr. Majumder.

Reference:

The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer - (https://www.lsuhsc.edu/newsroom/LSU%20Health%20Research%20Suggests%20A%20New%20Approach%20For%20Treatment-Resistant%20Breast%20Cancers.html)

Source-Eurekalert